28 research outputs found
Recommended from our members
Prevalence and Predictors of Loss of Wild Type BRCA1 in Estrogen Receptor Positive and Negative BRCA1-Associated Breast Cancers
Introduction: The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects the cell of origin of these tumors. However, approximately 20% of breast cancers that develop in BRCA1 carriers are ER-positive (ER+); these cancers are more likely to develop as BRCA1 carriers age, suggesting that they may be incidental and unrelated to BRCA1 deficiency. The purpose of this study was to compare the prevalence of loss of heterozygosity due to loss of wild type (wt) BRCA1 in ER+ and ER- breast cancers that have occurred in BRCA1 carriers and to determine whether age at diagnosis or any pathologic features or biomarkers predict for loss of wt BRCA1 in these breast cancers. Methods: Relative amounts of mutated and wt BRCA1 DNA were measured by quantitative polymerase chain reaction performed on laser capture microdissected cancer cells from 42 ER+ and 35 ER- invasive breast cancers that developed in BRCA1 carriers. BRCA1 gene methylation was determined on all cancers in which sufficient DNA was available. Immunostains for cytokeratins (CK) 5/6, 14, 8 and 18, epidermal growth factor receptor and p53 were performed on paraffin sections from tissue microarrays containing these cancers. Results: Loss of wt BRCA1 was equally frequent in ER+ and ER- BRCA1-associated cancers (81.0% vs 88.6%, respectively; P = 0.53). One of nine cancers tested that retained wt BRCA1 demonstrated BRCA1 gene methylation. Age at diagnosis was not significantly different between first invasive ER+ BRCA1 breast cancers with and without loss of wt BRCA1 (mean age 45.2 years vs 50.1 years, respectively; P = 0.51). ER+ BRCA1 cancers that retained wt BRCA1 were significantly more likely than those that lost wt BRCA1 to have a low mitotic rate (odds ratio (OR), 5.16; 95% CI, 1.91 to ∞). BRCA1 cancers with loss of wt BRCA1 were more likely to express basal cytokeratins CK 5/6 or 14 (OR 4.7; 95% CI, 1.85 to ∞). Conclusions: We found no difference in the prevalence of loss of wt BRCA1 between ER+ and ER- invasive BRCA1-associated breast cancers. Our findings suggest that many of the newer therapies for BRCA1 breast cancers designed to exploit the BRCA1 deficiency in these cancers may also be effective in ER+ cancers that develop in this population
Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features
Dissection of a QTL Hotspot on Mouse Distal Chromosome 1 that Modulates Neurobehavioral Phenotypes and Gene Expression
A remarkably diverse set of traits maps to a region on mouse distal chromosome 1 (Chr 1) that corresponds to human Chr 1q21–q23. This region is highly enriched in quantitative trait loci (QTLs) that control neural and behavioral phenotypes, including motor behavior, escape latency, emotionality, seizure susceptibility (Szs1), and responses to ethanol, caffeine, pentobarbital, and haloperidol. This region also controls the expression of a remarkably large number of genes, including genes that are associated with some of the classical traits that map to distal Chr 1 (e.g., seizure susceptibility). Here, we ask whether this QTL-rich region on Chr 1 (Qrr1) consists of a single master locus or a mixture of linked, but functionally unrelated, QTLs. To answer this question and to evaluate candidate genes, we generated and analyzed several gene expression, haplotype, and sequence datasets. We exploited six complementary mouse crosses, and combed through 18 expression datasets to determine class membership of genes modulated by Qrr1. Qrr1 can be broadly divided into a proximal part (Qrr1p) and a distal part (Qrr1d), each associated with the expression of distinct subsets of genes. Qrr1d controls RNA metabolism and protein synthesis, including the expression of ∼20 aminoacyl-tRNA synthetases. Qrr1d contains a tRNA cluster, and this is a functionally pertinent candidate for the tRNA synthetases. Rgs7 and Fmn2 are other strong candidates in Qrr1d. FMN2 protein has pronounced expression in neurons, including in the dendrites, and deletion of Fmn2 had a strong effect on the expression of few genes modulated by Qrr1d. Our analysis revealed a highly complex gene expression regulatory interval in Qrr1, composed of multiple loci modulating the expression of functionally cognate sets of genes
AI is a viable alternative to high throughput screening: a 318-target study
: High throughput screening (HTS) is routinely used to identify bioactive small molecules. This requires physical compounds, which limits coverage of accessible chemical space. Computational approaches combined with vast on-demand chemical libraries can access far greater chemical space, provided that the predictive accuracy is sufficient to identify useful molecules. Through the largest and most diverse virtual HTS campaign reported to date, comprising 318 individual projects, we demonstrate that our AtomNet® convolutional neural network successfully finds novel hits across every major therapeutic area and protein class. We address historical limitations of computational screening by demonstrating success for target proteins without known binders, high-quality X-ray crystal structures, or manual cherry-picking of compounds. We show that the molecules selected by the AtomNet® model are novel drug-like scaffolds rather than minor modifications to known bioactive compounds. Our empirical results suggest that computational methods can substantially replace HTS as the first step of small-molecule drug discovery
Moving knowledge into action for more effective practice, programmes and policy: protocol for a research programme on integrated knowledge translation
Essential items for reporting of scaling studies of health interventions (SUCCEED) : protocol for a systematic review and Delphi process
CITATION: Gogovor, A., et al. 2020. Essential items for reporting of scaling studies of health interventions (SUCCEED) : protocol for a systematic review and Delphi process. Systematic Reviews, 9:11, doi:10.1186/s13643-019-1258-3.The original publication is available at https://systematicreviewsjournal.biomedcentral.comBackground: The lack of a reporting guideline for scaling of evidence-based practices (EBPs) studies has prompted
the registration of the Standards for reporting studies assessing the impact of scaling strategies of EBPs (SUCCEED)
with EQUATOR Network. The development of SUCCEED will be guided by the following main steps recommended
for developing health research reporting guidelines.
Methods: Executive Committee. We established a committee composed of members of the core research team
and of an advisory group.
Systematic review. The protocol was registered with the Open Science Framework on 29 November 2019 (https://osf.
io/vcwfx/). We will include reporting guidelines or other reports that may include items relevant to studies assessing
the impact of scaling strategies. We will search the following electronic databases: EMBASE, PsycINFO, Cochrane Library,
CINAHL, Web of Science, from inception. In addition, we will systematically search websites of EQUATOR and other
relevant organizations. Experts in the field of reporting guidelines will also be contacted. Study selection and data
extraction will be conducted independently by two reviewers. A narrative analysis will be conducted to compile a list
of items for the Delphi exercise. Consensus process. We will invite panelists with expertise in: development of relevant
reporting guidelines, methodologists, content experts, patient/member of the public, implementers, journal editors,
and funders. We anticipated that three rounds of web-based Delphi consensus will be needed for an acceptable
degree of agreement. We will use a 9-point scale (1 = extremely irrelevant to 9 = extremely relevant). Participants’
response will be categorized as irrelevant (1–3), equivocal (4–6) and relevant (7–9). For each item, the consensus is
reached if at least 80% of the participants’ votes fall within the same category. The list of items from the final round will
be discussed at face-to-face consensus meeting. Guideline validation. Participants will be authors of scaling studies. We
will collect quantitative (questionnaire) and qualitative (semi-structured interview) data. Descriptive analyses will be
conducted on quantitative data and constant comparative techniques on qualitative data.
Discussion: Essential items for reporting scaling studies will contribute to better reporting of scaling studies and
facilitate the transparency and scaling of evidence-based health interventions.https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-019-1258-3Publisher's versio
Development and pilot testing of an online case-based approach to shared decision making skills training for clinicians
Linkage of a familial platelet disorder with a propensity to develop myeloid malignancies to human chromosome 21q22.1-22.2
Linkage analysis was performed on a large pedigree with an autosomal dominant platelet disorder and a striking propensity in affected family members to develop hematologic malignancy, predominantly acute myelogenous leukemia. We report the linkage of the autosomal dominant platelet disorder to markers on chromosome 21q22. Four genetic markers completely cosegregate with the trait and yield maximum logarithm of difference scores ranging from 4.9 to 10.5 (θ = .001). Two flanking markers, D21S1265 and D21S167, define a critical region for the disease locus of 15.2 centimorgan. Further analysis of this locus may identify a gene product that affects platelet production and function and contributes to the molecular evolution of hematologic malignancy.7 page(s